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Abstract
Background: Scientists have been trying to understand the molecular mechanisms of diseases to design preventive and
therapeutic strategies for a long time. For some diseases, it has become evident that it is not enough to obtain a catalogue
of the disease-related genes but to uncover how disruptions of molecular networks in the cell give rise to disease
phenotypes. Moreover, with the unprecedented wealth of information available, even obtaining such catalogue is
extremely difficult.
Principal Findings: We developed a comprehensive gene-disease association database by integrating associations from
several sources that cover different biomedical aspects of diseases. In particular, we focus on the current knowledge of
human genetic diseases including mendelian, complex and environmental diseases. To assess the concept of modularity of
human diseases, we performed a systematic study of the emergent properties of human gene-disease networks by means
of network topology and functional annotation analysis. The results indicate a highly shared genetic origin of human
diseases and show that for most diseases, including mendelian, complex and environmental diseases, functional modules
exist. Moreover, a core set of biological pathways is found to be associated with most human diseases. We obtained similar
results when studying clusters of diseases, suggesting that related diseases might arise due to dysfunction of common
biological processes in the cell.
Conclusions: For the first time, we include mendelian, complex and environmental diseases in an integrated gene-disease
association database and show that the concept of modularity applies for all of them. We furthermore provide a functional
analysis of disease-related modules providing important new biological insights, which might not be discovered when
considering each of the gene-disease association repositories independently. Hence, we present a suitable framework for
the study of how genetic and environmental factors, such as drugs, contribute to diseases.
Availability: The gene-disease networks used in this study and part of the analysis are available at http://ibi.imim.es/
DisGeNET/DisGeNETweb.html#Download.
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Introduction
For many years, scientists have been trying to understand the
molecular and physiopathological mechanisms of diseases in order
to design new preventive and therapeutic strategies. The
combination of experimental and computational methods has
led to the discovery of disease-related genes [1,2]. A well-known
example is Phenylketonuria, where the function of the gene
encoding the PAH enzyme was studied with respect to the
mechanism of the disease [3]. However, we are still far from fully
understanding disease causation, especially regarding complex
diseases such as cancer [2]. Even for mendelian diseases this is not
fully achieved because phenotypic outcome cannot be predicted
solely based on the genotype [3]. It has become evident, that many
human diseases cannot be attributed to malfunction of single genes
but arise due to complex interactions among multiple genetic
variants [4]. Moreover, influences of environmental factors,
infectious agents or drugs have to be considered when studying
the occurrence and evolution of a disease. In complex diseases,
alterations in several genes can make subtle contributions to the
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a disease is caused and thus how it can be treated can only be
studied on the basis of the entire body of knowledge including all
genes that are associated with the disease and their interactions
through biological pathways. However, with the unprecedented
wealth of information available, it is extremely difficult to obtain a
complete picture of the genetic basis of diseases. In order to obtain
such a complete picture, data integration from different sources is
required. This is of special interest considering the fact that
individual researchers are often restricted to so called knowledge
pockets [5] covering only a small fraction of all available
knowledge that is spread all over the literature or various
databases. This fragmentation of information clearly hampers
our understanding of the molecular processes underlying human
diseases.
In the 60s, Dr. McKusick, the initiator of the Online Mendelian
Inheritance in Man (OMIM) database, started collecting infor-
mation about genes and their association to diseases first as a book
and later as a database. OMIM has become a highly popular
source in medical genetics [6]. It traditionally focused on
mendelian diseases and later started to include complex diseases
as well. In the last years, other databases have been built, among
them the Pharmacogenomics Knowledge Base (PHARMGKB)
specialized on the knowledge about genes that are involved in
modulating drug response [7] or the Comparative Toxicoge-
nomics Database (CTD) focused on the effect of environmental
chemicals on human disease [8]. Each of the databases focuses on
different aspects of phenotype-genotype relationships. However,
due to the fast increase of literature in the life science domain, no
one (not even expert curators of such databases) can keep track of
the relevant knowledge that is regularly published [5]. Here, text-
mining has evolved as a useful tool to automatically extract the
information about the relationships between biomedical entities
reported in the literature (for a recent overview see [9]). In this
work we developed a comprehensive database of human gene-
disease associations by integrating both, information from different
databases and from literature, in order to bridge the gaps between
the aforementioned knowledge pockets. The resulting database
(DisGeNET database) comprises the whole spectrum of human
diseases with genetic origin, including mendelian, complex and
environmental diseases, and represents, to the best of our
knowledge, the most complete view on human gene-disease
associations that is currently publicly available.
Many phenotypically similar diseases are caused by functionally
related genes, such as Stickler, Marshall and OSMED syndromes
[10,11,12], or several forms of human ataxias [13]. Hence, many
diseases are caused by dysfunction of so-called functional modules
[13,14,15,16]. Functional modules can be defined as a group of
cellular components and their interactions that carry out a specific
biological function [17]. These functional modules can be either
physically constrained like the ribosome or spread over the cell like
a signal transduction pathway. Alterations in the individual
components of a specific functional module can result in similar
disease phenotypes. Accordingly, several studies proposed the
concept of modularity for human genetic diseases taking
malformation syndromes as examples [18,19,20].
The concept of modularity of human diseases is the basic
assumption of several methods for the identification and
prioritization of candidate disease genes [2]. Surprisingly, the
concept of modularity of human diseases has not been evaluated
systematically for all the diseases, except for the ones available at
OMIM (see [21] for a recent review) and individually for some
diseases (see below). Moreover, while the concept of modularity
proved to be useful when studying mendelian or oligogenic traits,
there is still limited evidence for its applicability for complex traits
[20]. Most of the current approaches to identify disease relevant
modules focus on individual diseases [13,14,15,16]. A different
strategy was proposed by [22], who performed a global analysis of
a human gene-disease associations based on the OMIM database
to show that gene products related to the same disease have a
higher likelihood to physically interact [22].
In this article, we pick up the concept of modularity of human
genetic diseases with the aim of assessing it for the whole spectrum
of diseases with genetic origin, which had not been studied before.
For this purpose we use networks, which allow the representation
of the relationships between biomedical entities [22,23,24] and the
subsequent analysis of emergent properties [25]. It has been
observed that topological properties of biological networks differ
from those in random networks [26]. Moreover, it has been shown
how cluster analysis of protein-protein interaction networks can be
used to identify functional modules [23,27]. Hence, we use
topological and functional analysis of gene-disease association
networks to assess the modularity of mendelian, complex and
environmental diseases. Our results indicate that for most human
diseases functional modules do exist. This is also observed for
groups of diseases sharing gene associations. Moreover, our results
point out that most human diseases are associated with more than
one biological process. This contrasts with previous observations
based on OMIM data. We show in several case studies how the
network representation of human genetic diseases and the adjacent
detection of functional modules can be used not only to shed light
on the molecular basis of human diseases but also to gain a better
understanding of the influence of environmental factors, including
drugs, on human health. Moreover, our analysis confirms the need
of integrating human gene-disease associations from various
sources. To enforce research in this field, we make all gene-
disease networks publicly available as SQLite database for
computational access, as well as through DisGeNET, a plugin
for Cytoscape [28] to access and analyze our data.
Results and Discussion
Topological network analysis
Previous work has shown that topological network analysis of
gene-disease associations uncovers important properties of the
nature of mendelian diseases [22]. We used four different bipartite
networks called OMIM, CURATED, LHGDN and ALL (see
Methods) to study human diseases at a global scale, including
mendelian, complex and environmental diseases. By comparing the
four networks we show that our integration effort results in a huge
increase in coverage of (i) diseases, (ii) genes and (iii) their
associations compared to the individual data sources (see Fig. S2).
The overlap among databases is surprisingly small (see Fig. S3)
confirming the existence of the aforementioned knowledge pockets
and highlighting the need of integrating different data sources. We
demonstrate how the integration can close knowledge gaps in Case
study 2 (section Case studies). Here, the association between MITF,
a transcription factor regulating the expression of the TYR gene,
and Melanoma [29,30] was not found in any of the curated
databases but was present in the text-mining derived network. The
more data sources are considered the denser the networks become,
indicating that many more diseases share genetic origin than
reflected in a single source (Fig. 1). In OMIM, most diseases are
associated with few genes. Contrasting, in the other networks most
diseases are part of a large connected component that increases
noticeably when integrating more data. Concomitantly the number
of diseases associated with only one gene decreases (see curly
brackets in Fig. 1) suggesting that most diseases are associated with
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already observed in the network CURATED. Previous studies have
reported that for some mendelian disorders, such as Phenylketon-
uria, the observed phenotype is the result of the combined effect of a
primary gene and other genes that act as modifiers [3,31]. Our
results indicate that the same phenomenon might be in place for
other mendelian disorders. In addition, our results support the
hypothesis that the distinction between mendelian and multiple
gene disorders is rather artificial and that the influence of several
genes, including the so-called modifier genes, should be studied in
more detail for mendelian disorders [3,31].
We furthermore show that the degree distributions of diseases
and genes are different from the degree distribution of random
networks, but none of them follows a power law distribution (see
Fig. S5). Although many early studies about the topology of
biological networks proposed power-law behavior, recent re-
evaluations indicate that this is not always the case and other
models need to be considered [32,33]. Nevertheless, there are two
main trends visible. Both, the number of hubs and the average
degree size increase dramatically due to the integration process.
For the gene nodes, the average degree ranges from 1.6 in OMIM
to 5.6 in ALL and for the disease nodes, from 1.5 in OMIM to
10.1 in ALL (see Fig. S5). The degree of a disease node represents
the number of associated genes and hence can be used as a
measure for the locus heterogeneity of the disease. Overall, there is
a dramatic increase in the maximum locus heterogeneity. With
respect to the genes, the increase in the node degree is less
dramatic but still visible (see Fig. S5).
To study the diseases and disease-related genes in more detail,
we also generated gene and disease centric views of the data by
projecting the bipartite gene-disease networks to monopartite
networks. Similarly to the observations in the bipartite networks,
the node degrees increase dramatically when integrating more
data. All in all, our results suggest a much higher level of
interrelation of human diseases than observed by solely consider-
ing a single data source (e.g. OMIM).
In summary, the network analysis of our integrated database
points out that data integration is needed to obtain a comprehen-
sive view of the genetic landscape of human diseases and that the
genetic origin of mendelian, complex and environmental diseases
is much more common than expected.
Functional network analysis
A. Functional analysis at the level of individual
diseases. Several studies based on the OMIM database
indicated that for diseases with high locus heterogeneity the
associated genes are involved in the same biological process,
supporting the concept of functional modules associated with
disease [22,34,35]. This concept of modularity is often assumed to
be valid for all human diseases; however it has not been tested
before for monogenic, complex and environmental diseases in a
systematic manner. The DisGeNET database represents an
appropriate resource to perform such an evaluation. Thus, we
wanted to assess if the disease-related genes in our integrated data
set were involved in the same biological processes. In other words,
we wanted to study if the concept of modularity applies to the
whole spectrum of human genetic diseases. For this purpose, we
calculated pathway homogeneity with the following average
values: 0.77 (sd 0.26) in OMIM, 0.67 (sd 0.27) in CURATED,
0.56 (sd 0.24) in LHGDN and 0.59 (sd 0.25) in ALL. Interestingly,
in comparison to the OMIM dataset, the homogeneity values
decreased for the larger networks (CURATED, LHGDN, ALL).
To assess if the decrease of homogeneity values results from the
integration effort, we studied the dependency of homogeneity
Figure 1. Cytoscape screenshot depicting the four gene-disease networks. Gene (blue) and disease (magenta) nodes are connected by
edges in different colors corresponding to the type of association in our gene-disease association ontology. Grey represents Marker association, red
denotes GeneticVariation, blue corresponds to Therapeutic class, green to RegulatoryModification.
doi:10.1371/journal.pone.0020284.g001
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sources, even for OMIM, the homogeneity decreases with
increasing number of associated gene products (r=20.25) (see
Fig. 2). Nevertheless, homogeneity values are significantly higher
than for random controls (see Fig. 2), indicating that genes related
to the same disease are more likely to be involved in the same
biological pathways than randomly selected disease genes. For
instance, in CURATED, diseases with two to five annotated gene
products have an average pathway homogeneity of 0.75 (sd 0.26),
suggesting that on average 75% of the gene products are
annotated to the same pathway, while this value decreases to
0.38 (sd 0.15) if 50 to 100 gene products are annotated to the
disease (see Fig. 2). For diseases with two to five annotated gene
products, approximately 70% of them participate in the same
pathway for all data sources. On the other hand, for diseases with
more than 10 gene products annotated, it is more likely that more
than one pathway is involved. Moreover, it is striking that
although the text-mining derived network is very dense with an
average of 18.7 genes per disease, the homogeneity values still
differ significantly from random, with values comparable to the
ones in CURATED. The observed decrease of homogeneity was
observed for all databases including OMIM suggesting that it is
not related to the integration effort but arises due to increased
locus heterogeneity of diseases. This observation should be taken
into account in future studies of genetic diseases.
Strikingly for all datasets the homogeneity values differ
significantly from random controls supporting that for most
diseases functional modules exist. Thus, the concept of modularity
is observed for mendelian diseases, in agreement with previous
reports [13,18,22,34,35], but also for complex and environmental
diseases. Moreover, the analysis shows that a core set of biological
pathways is associated with most human diseases. Similar
observations were reported for different cancer types, such as for
Pancreatic Cancer [14] or Glioblastoma [36]. Our results show
that this is also the case for the diseases present in DisGeNET.
Similar results were recently reported by [37] showing on average
12 pathways associated with a disease, using a database based on
co-occurrence of genes and diseases in the literature.
B. Functional analysis at the cluster level
B.1. Functional analysis of disease clusters. We applied
the MCL graph-clustering algorithm (see Methods) to identify
highly connected units, so called clusters, in the disease projection
networks and then tested if the disease clusters are associated with
functionally relevant modules. For this purpose, we determined if
the genes associated with the disease clusters are more likely to
participate in the same biological processes than randomly selected
genes by calculating pathway homogeneity (see Fig. S6). On
average, pathway homogeneity is 0.68 (sd 0.24) for OMIM and
0.59 (sd 0.25) for CURATED, suggesting that in these datasets
60–70% of the gene products belonging to a disease cluster
participate in the same pathway. For the more populated networks
(LHGDN and ALL) the average pathway homogeneity values of
disease clusters decreases to approximately 0.48 (sd 0.23).
However, we again observe a decrease of the pathway
homogeneity with increasing number of gene products
annotated to the diseases clusters (r=20.26) (see Fig. S6). A
more detailed analysis of the disease clusters revealed that the
majority has medium pathway homogeneity values and there are
only few extremely homogeneous or heterogeneous disease
clusters. Overall, the results for single diseases and disease
clusters are similar. Hence, for most diseases and even for
clusters of diseases, more than one biological pathway is
associated. It can be argued that for these diseases cross-talks of
pathways could play an important role. For instance, the cross-talk
between Integrin and TGF-b pathways has been found to be
Figure 2. Pathway homogeneity for individual diseases. Mean pathway homogeneity values of single diseases and random controls are
plotted for all four networks binned by the number of associated gene products per disease. Pathway homogeneity values range from 0 to 1, where 1
means that all gene products associated with the disease are annotated to the same pathway. Confidence intervals of 95% were added to allow
comparison of real to random values. For OMIM, there are only two diseases with more than 30 gene products annotated, both with a pathway
homogeneity of 1.
doi:10.1371/journal.pone.0020284.g002
Modularity in Human Diseases
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20284related to several human pathologies including systemic sclerosis,
idiopathic pulmonary fibrosis, chronic obstructive pulmonary
disease and cancer [38].
B.2. Functional analysis of gene clusters. Studies focused
on a specific disease presented evidence arguing for a modular
nature of the disease, especially for congenital malformations and
related syndromes [13,18]. In the previous sections, we evaluated
from a disease centric view if functional modules exist for human
genetic diseases. In this section, we assess the modularity from the
gene centric view by evaluating if groups of phenotypically related
genes represent functional modules in the cell. For this purpose we
analyzed the functional annotations of gene products in clusters
derived from applying the graph-clustering algorithm on the gene
projection networks (see Methods).
Gene products can be functionally related to each other in
different ways: by means of direct, physical protein-protein
interactions or by more indirect associations as observed between
enzymes in the context of a metabolic pathway.
First we assessed to which degree the proteins encoded by the
genes in the clusters directly interact in the cell. For this purpose,
we used a recently published human interaction network (HIN)
based on protein-protein and signaling interactions [36] and
calculated HINscores for the gene clusters (see Methods). The
HINscore ranges from 0, where none of the gene products in a
cluster directly interacts in HIN, to 1, if all gene products
physically interact in HIN and hence the gene cluster represents a
biologically functional module. Therefore, the HINscore can be
used to measure the modularity of human diseases in our
networks. For CURATED and OMIM, clusters including less
than 50 nodes show HINscores significantly higher than for
random clusters, while for the other networks the difference is
significant for clusters of less than 15 nodes (see Fig. 3A). Fig. 3B
illustrates some selected clusters from CURATED with high
HINscores. For instance, cluster B.1 contains genes mainly
associated with mitochondrial complex I deficiency (genes in the
lower right part of the gene cluster), and Leigh and Alexander
diseases (genes in the upper left part of the gene cluster). The latter
are neurometabolic disorders that result from defects in the
mitochondrial respiratory chain. Genes associated with these
diseases encode proteins that form a physically interacting module
as illustrated by the HIN subgraph. Other examples of clusters
with high HINscore are related to peroxisomal disorders (e.g.
Zellweger syndrome), different types of anemia (Diamond-Black-
fan anemia or Heinz body anemia) or Walker-Warburg and
Fukuyama syndromes. Thus, the HINscore can be used to identify
phenotypically derived gene clusters, in which direct interactions
between the gene products might play an important role.
Second, we evaluated the indirect relationships between disease
gene products. For this purpose we calculated pathway homoge-
neity of the phenotypically related gene clusters. In CURATED,
60% of the clusters have pathway homogeneity values ,0.75.
Hence for more than half of the clusters, there are at least two
pathways annotated. In CURATED, the average pathway
homogeneity for clusters smaller than 50 nodes is significantly
higher than for randomly selected clusters (see Fig. S7). For clusters
larger than 50 nodes the results are not significantly different from
random controls; however, such clusters are underrepresented in
our dataset. Moreover, similar to individual diseases and disease
clusters, we observe that the homogeneity decreases with increasing
size of the cluster for all data sets (r=20.20).
C. Summary and outlook
Most of the gene clusters (72%) in CURATED are of size
smaller than 15. Interestingly, for such clusters, HINscores and
homogeneity values differ significantly from random for all four
networks. In general, clusters with high HINscore or pathway
homogeneity are homogeneous in terms of associated diseases,
meaning that the genes are annotated to similar diseases. For
example, gene products of cluster B.1 depicted in Fig. 3, which
corresponds to mitochondrial respiratory chain deficiencies and
Alexander and Leigh Disease, physically interact and hence the
HINscore is very high. In addition, they are all annotated to the
same pathway resulting in a pathway homogeneity value of 1. In
contrast, clusters with very low homogeneity values (,0.25) are
heterogeneous in terms of disease annotation. These clusters,
which are underrepresented in the dataset, contain genes with very
high allelic heterogeneity. In CURATED, for instance, genes
having more than 20 associated diseases, belong to heterogeneous
clusters with low pathway homogeneity values (mean=0.28,
sd=0.11). Thus, the genes in these clusters are annotated to
different biological pathways. It could be argued that such genes
encode multifunctional proteins that participate in different
biological processes, and mutations in these proteins affecting
different functions can then lead to different disease phenotypes.
This set of genes might be classified as pleiotropic genes [39] or
represent genes that ‘‘moonlight’’ between different functions [40].
The diversity of functional annotation of these genes might be
‘‘obscuring’’ the modularity of the associated diseases. Thus, it
would be interesting to further investigate the role of these proteins
with respect to disease development. Nevertheless, the majority of
clusters show medium range HINscore and pathway homogeneity
values, suggesting that not a single biological process but a core-set
of biological processes is relevant for the disease. This has
important implications for disease treatment and drug develop-
ment. If a disease is associated with several pathways, a therapy
considering the diversity of biological processes could be of
advantage [41]. And if a set of diseases is related to the same
pathways, a treatment already successful for one of the diseases
could also be applied to the other diseases [42].
We studied the concept of modularity from the disease and the
gene centric perspectives. All in all, our results show that for most
diseases,and even forclustersofrelateddiseases,functional modules
do exist. Moreover, we show that phenotypically related gene
clusters resemble functional modules. Hence, these functional
modules can be studied more deeply to shed light on the
mechanisms related to the diseases. We therefore determined the
specific biological processes relevant for each gene cluster by
calculating GO term and pathway enrichment (see Text S1, Section
2.3). We obtained significant (p-value,0.05) GO and pathway
enrichment for 94% of the clusters in CURATED. Details on the
clusters and the enrichment results are also available online.
There are some limitations to our analysis related to the
incompleteness of our databases due to natural limitations in the
curation process of the original databases, and related to
inaccuracies derived from text-mining. Moreover, annotation issues
have tobe considered,such as the incomplete annotation ofgenesto
GO terms, biological pathways and HIN, and the incomplete
coverage of cross-talks and other annotation issues in pathway
databases [43]. Even taking into account the aforementioned
limitations, to the best of our knowledge, this is the first global
analysis of human genetic diseases including mendelian, complex
and environmental diseases. Overall, we observe good quality of
text-mining derived associations, as values for LHGDN are
comparable to the networks derived from expert-curated databases.
Case studies
Our comprehensive database represents a suitable framework to
study human diseases with genetic origin and also the influence of
Modularity in Human Diseases
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some examples making use of our integrated database and the
results of the enrichment analysis to inspire future studies and to
encourage other researchers to use DisGeNET. Illustrative case
studies for the (i) analysis of mechanisms underlying adverse drug
reactions, (ii) prediction of disease candidate genes, (iii) study of the
interactions between environmental factors and diseases at the
genetic level, and (iv) identification of shared mechanisms of
distinct diseases are presented. Moreover, we provide a Cytoscape
session file including all examples discussed in this article (http://
ibi.imim.es/DisGeNET/data/DisGeNET.cys).
Case study 1: Analysis of mechanisms underlying adverse
drug reactions. Rhabdomyolysis can result from a traumatic
injury, but also appears as a consequence of other diseases or due
to intoxication with recreational and prescription drugs, such as
Perhexiline. One of the three genes associated with Rhabdo-
myolysis is CPT2, which encodes the mitochondrial carnitine
palmitoyltransferase II (see Fig. 4). Inherited deficiencies in this
enzyme lead to CPT2 deficiency, an autosomal recessive disorder
characterized by recurrent Myoglobinuria, episodes of muscle
pain, stiffness, and Rhabdomyolysis. On the basis of this
knowledge it is possible to create a hypothesis on the mechani-
sms by which certain drugs such as Perhexiline can lead to
Rhabdomyolysis. Perhexiline, which is prescribed for severe
Angina Pectoris [44] inhibits CPT1, shifting myocardial
substrate utilization from long chain fatty acids to carbohydrates
(http://www.drugbank.ca/drugs/DB01074). Perhexiline can also
target, to a lesser extent, CPT2 [45], which would explain the
Figure 3. HINscores for phenotypically derived gene clusters. A: Mean HINscores plotted for different cluster sizes for all networks and
random controls. B: Selected gene clusters denoted as B.1, B.2, B.3 and their corresponding HIN subgraphs from the CURATED dataset. In the
phenotypically derived gene clusters (upper part) red edges represent physical interactions among the gene products. In the HIN subgraphs (lower
part), red edges denote phenotypic relationship among the corresponding genes. Nodes in light blue belong to the phenotypically derived gene
clusters that are not present in HIN. B.1 is associated with mitochondrial respiratory chain deficiencies, Leigh and Alexander Disease. B.2 corresponds
to Hypertension and Cardiovascular Diseases. B.3 represents different types of Hyperlipoproteinemia. Nodes are colored according to their disease
class (see Fig. S4).
doi:10.1371/journal.pone.0020284.g003
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CPT2 with Rhabdomyolysis. Note that the association of CPT2
with Rhabdomyolysis was not available in any of the curated
databases but in our integrated data set. This example shows the
potential of using our gene-disease data in combination with drug-
target data for the analysis of drug adverse reactions.
Case study 2: Gene clusters and pathway analysis to
predictnew disease candidate genes. One of the gene clusters
is composed of 20 genes associated with a variety of diseases such as
melanoma and developmental diseases affecting pigmentation, eye
and ear functions (Tietz and Waardenburg syndromes). Most genes
of the cluster are associated with melanoma with the exception of
MITF (see Fig. 5A). GO enrichment analysis resulted in terms like
‘‘melanin biosynthetic process from tyrosine’’ (GO:0006583), ‘‘eye
pigment biosynthetic process’’ (GO:0006726) and ‘‘melanocyte
differentiation’’ (GO:0030318), among others. These are all
processes relevant to skin, hair and eye pigmentation, hearing
function in the cochlea, and skin carcinogenesis. Fig. 5B shows the
Melanogenesis pathway (KEGG hsa:04916), which is the most
significantlyenrichedpathwayforthiscluster.Theproteinsencoded
by genes TYR and ASIP (ASP in KEGG) and the transcription
factor encoded by MITF regulating expression of the TYR gene,
are highlighted in red in the pathway. Since MITF appears not only
in the same phenotypically derived cluster but also in the same
pathway as the genes associated with Melanoma, it could be
proposed that MITF is a candidate disease gene for Melanoma. In
fact, we could confirm this finding by checking the disease
neighborhood of MITF in the gene-disease network (ALL) that
also includes text-mining derived information (see Fig. 5C). The
information extracted by text-mining indicates that MITF has been
reported as a gene involved in melanocyte development and
characterized as melanoma oncogene [29,30]. In conclusion,
clustering analysis of the gene projection network followed by
functional enrichment analysis can be used to propose new
candidate disease genes. We would also like to mention here that
the CURATED set of DisGeNET represents a suitable dataset to
benchmark computational methods for the prediction of candidate
disease genes.
Casestudy3:Interactionbetweenenvironmentalexposure
with arsenic compounds and cancer at the genetic
level. Another gene cluster contains 67 genes mostly associa-
ted with Arsenic Poisoning, skin and nervous system diseases, and
different types of neoplasm. Arsenic is a well established human
carcinogen, and many studies support an association between
arsenic exposure and increased incidence of solid tumors, such as
lung, bladder, prostate, renal and skin tumors [46,47,48,49,50,51].
Moreover, studies conducted in developing countries show a
general increase in the incidence of different types of cancers,
which is hypothesized to be associated with exposure to environ-
mental toxins, among other factors, some of them of genetic origin
[52,53,54]. Thus, there is a need to investigate the interactions
among environmental carcinogens and genetic factors [53].
Although more studies are needed to determine a linkage between
arsenic exposure and Breast Cancer incidence [55], this cluster
indicates a possible association at the genetic level. Some of the
genes that are associated with Arsenic Poisoning are also known to
be associated with Breast Cancer, such as TNF, CCL20, CXCL2,
CXCL3 and IL1B. Apoptosis-inducing factors IL1B and TNF are
down regulated by arsenic compounds [56], as indicated by the
supporting evidence of one of the associations in the dataset. This
observation combined with theknowledgeonDNAdamaging effect
of arsenic [57] may provide a mechanistic hypothesis for the
tumorigenic effects of arsenic.
All in all, cluster analysis of the gene projection network uncovered
an interesting relationship between environmental exposure to
arsenic compounds and breast cancer. This relationship deserves
further investigation at the epidemiological and molecular levels.
Case study 4: Identification of shared mechanisms of
different diseases. Another cluster containing 79 genes is an
example of a heterogeneous cluster in which genes are associated
with different diseases. Fig. 6 shows the three main disease groups,
Atopic Dermatitis (an autoimmune skin disease), Diabetes Mellitus
Type I (an early onset, insulin-dependent, autoimmune disease),
and Inflammatory Bowel Diseases (including Crohn Disease and
Ulcerative Colitis). All these diseases are related as they share
many gene associations. Interestingly, according to MeSH, one of
Figure 4. Knowledge about genetic basis of diseases can shed light on mechanisms underlying drug adverse reactions. A network of
genes and diseases around Rhabdomyolisis is displayed. The drug Perhexiline is used for treatment of Angina Pectoris and has as therapeutic target
CPT13. In addition, it can also target CPT2. Since deficiencies in CPT2 function are associated with Rhabdomyolisis, it can be proposed that Perhexiline
causes Rhabdomyolisis through its action on CPT2.
doi:10.1371/journal.pone.0020284.g004
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Disease but only as Digestive Systems Disease (genes colored in
pink). However, it is well established that Crohn Disease is an
autoimmune disease [58,59], and this grouping is captured by the
network analysis.
GO term and pathway enrichment analysis showed that for this
heterogeneous cluster, there are common biological processes
associated with the distinct diseases. For instance, although there
are 59 pathways annotated to this cluster, the pathway
homogeneity is 41% indicating that almost half of the gene
products appear in the same pathway. The most significantly
enriched processes are related to immune (GO:0006955) and
inflammatory response (GO:0006954), while the most significantly
enriched pathway is the Jak-STAT signaling pathway (KEGG
hsa:04630). Fig. 6 shows the Jak-STAT signaling pathway, which
contains genes associated with all three diseases of this cluster.
Interestingly, the connections of the different diseases can be seen
on different levels of this signaling pathway, from receptor-ligand
interactions towards downstream signaling and transcriptional
regulation. This example shows the value of clustering and
subsequent GO and pathway enrichment analysis to identify
mechanisms that are common to different diseases.
Conclusions
The first goal of this study was to develop a comprehensive
resource covering the current knowledge on human genetic
diseases and to provide it to the community. The second goal of
this study was to address the concept of modularity in all human
diseases with genetic origin. Although in the biomedical literature
it is often assumed that human diseases are modular, the validity of
this hypothesis has not been tested before in a systematic manner
for all diseases with genetic origin. We have performed a detailed
study of the emergent properties of human gene-disease networks
by means of computational analysis, covering the whole spectrum
of human diseases with genetic origin including monogenic,
complex and environmental diseases. The results indicate a highly
shared genetic origin of monogenic, complex and environmental
diseases. Moreover, most diseases cannot be attributed to a single
gene but to defects of several genes. Interestingly, these genes are
likely to participate in a core set of biological processes. This is
even observed in several mendelian disorders, contrasting to
previous findings. More strikingly, similar findings are obtained
when studying groups of diseases. This suggests that the diseases in
these groups, which can be very similar but also very unrelated,
might arise due to dysfunction of the same biological processes in
the cell. Finally, we identified the core biological processes
associated to the diseases in DisGeNET and show in several
examples the value of such analysis to unveil the mechanisms
leading to disease phenotypes and adverse drug reactions. Our
computational analysis has important implications for understand-
ing disease mechanisms and how environmental factors, such as
drugs, influence human health. Finally, we provide all gene-disease
networks in a user-friendly way through DisGeNET [28], a
Cytoscape plugin and as SQLite database for direct computational
access to aid future research of disease-related processes that will
also benefit drug discovery and development.
Methods
Data integration
DisGeNET, a comprehensive database of gene-disease associ-
ations was developed by integrating information from four
Figure 5. Candidate disease gene prediction. A: Phenotypically derived gene cluster associated with Melanoma. MITF is the only gene in the
cluster not associated with Melanoma. B: The Melanogenesis pathway (KEGG: hsa:04916) with genes MITF, TYR and ASP (ASIP in A) colored in red. C:
Neighborhood of MITF gene in network ALL.
doi:10.1371/journal.pone.0020284.g005
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UniProt/SwissProt (UNIPROT) [60], Pharmacogenomics Knowl-
edge Base (PHARMGKB) [61], and Comparative Toxicoge-
nomics Database (CTD) [8]. In addition, associations from a
literature-derived human gene-disease network (LHGDN) [62]
were included to increase the coverage of the database. For a
correct integration of gene-disease association data, we developed
a gene-disease association ontology (see Fig. S1). The data sources,
gene-disease association ontology and data integration approach
are described below.
Data sources
OMIM: Online Mendelian Inheritance in Man (OMIM)
focuses on inherited diseases. Gene-disease associations were
obtained by parsing the mim2gene file for associations of type
‘‘phenotype’’ (data was downloaded from ftp://ftp.ncbi.nlm.nih.
gov/gene/DATA/mim2gene on June, 6th 2009) and classified as
Marker in our gene-disease association ontology (see Fig. S1). In
total, we obtained for 2198 distinct genes and 2473 distinct disease
terms 3432 gene-disease associations. After mapping of disease
vocabularies, the OMIM network contained 2417 distinct diseases.
UNIPROT: UniProt/SwissProt is a database containing
curated information about protein sequence, structure and
function. Moreover, it provides information on the functional
effect of sequence variants and their association to disease. We
extracted this information from UniProt/SwissProt release 57.0
(March 2009) as described in [63]. All protein identifiers were
converted to Entrez Gene identifiers in order to allow integration
with the other data sources. All gene-disease associations were
classified as GeneticVariation. UniProt provided 1746 distinct
gene-disease associations for 1240 distinct genes and 1475 distinct
diseases.
PHARMGKB: The Pharmacogenomics Knowledge Base
(PharmGKB) is specialized on the knowledge about genes that
are involved in modulating drug response (pharmacogenes). Genes
are classified as pharmacogenes because they are (i) involved in
the pharmacokinetics of a drug (how the drug is absorbed,
distributed, metabolized and eliminated) or (ii) the pharmacody-
namics of a drug (how the drug acts on its target and its
mechanisms of action) [61]. Hence, it covers less broadly human
gene-disease associations but was found to be complementary to
the other sources, as it contains some gene-disease associations not
present in the other repositories. We downloaded genes.zip,
diseases.zip and relationships. zip from http://www.pharmgkb.
org/resources/downloads_and_web_services.jsp on June 6th 2009
and parsed the files to extract gene-disease associations. We
furthermore made use of the Perl webservices to obtain all
available annotations and supporting information. We included
1772 associations for 79 distinct genes and 261 distinct diseases.
PharmGKB associations were classified as Marker if the original
label was ‘‘Related’’ and as RegulatoryModification if the original
label was ‘‘Positively Related’’ or ‘‘Negatively Related’’.
CTD: The Comparative Toxicogenomics Database (CTD) con-
tains manually curated information about gene-disease relation-
ships with focus on understanding the effects of environmental
chemicals on human health. We downloaded the CTD_gene_
disease_relations.tsv file from http://ctd.mdibl.org/downloads/
on June 2nd 2009 and parsed it for gene-disease associations of
type ‘‘marker’’ or ‘‘therapeutic’’ (see http://ctd.mdibl.org/help/
glossary.jsp for description of the original labels). CTD includes
associations from OMIM but with some differences (i) for some
associations extra information such as cross-links to PubMed are
available and (ii) some associations are missing in either of the two
databases. Hence, we kept all available gene-disease associations
from both sources. All CTD gene-disease associations were
classified as Marker if the original label was ‘‘marker’’ and as
Therapeutic if the original label was ‘‘therapeutic’’. All cross-links
to PubMed were kept. In total CTD data provided 6469
associations for 2702 distinct diseases and 3345 distinct genes.
LHGDN: The literature-derived human gene-disease network
(LHGDN) is a text mining derived database with focus on
extracting and classifying gene-disease associations with respect to
several biomolecular conditions. It uses a machine learning based
algorithm to extract semantic gene-disease relations from a textual
Figure 6. Identification of shared mechanisms of different diseases. A cluster containing genes associated with distinct diseases is shown on
the left part of the figure. There are three main disease groups, Atopic Dermatitis (an autoimmune skin disease), Diabetes Mellitus Type I (an early
onset, insulin-dependent, autoimmune disease), and Inflammatory Bowel Diseases (including Crohn Disease and Ulcerative Colitis). Diseases are
coloured according to their disease class (see Fig. S4). The most significantly enriched Jak-STAT signaling pathway is displayed with some nodes from
the cluster colored in red (right part).
doi:10.1371/journal.pone.0020284.g006
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extracted with F-measures of 78 (see [62] for further details). More
specifically, the textual source utilized here originates from Entrez
Gene’s GeneRIF (Gene Reference Into Function) database [64].
This database represents a rapidly growing knowledge repository
and consists of high-quality phrases created or reviewed by MeSH
indexers. Hereby, the phrases refer to a particular gene in the
Entrez Gene database and describe its function in a concise
phrase. Using this textual repository for text mining has recently
gained increasing attention, due to the high quality of the provided
textual data in the GeneRIF database [62,65,66]. LHGDN was
created based on a GeneRIF version from March 31st, 2009,
consisting of 414241 phrases. These phrases were further restricted
to the organism Homo sapiens, which resulted in a total of 178004
phrases. We extracted all data from LHGDN and classified the
original associations using our ontology. In total, LHGDN
provided 59342 distinct gene-disease associations for 1850 diseases
and 6154 distinct genes. The LHGDN is also available in the
Linked Life Data Cloud (http://linkedlifedata.com/sources).
Gene-disease association ontology
For a correct integration of gene-disease association data, we
developed a gene-disease association ontology (see Fig. S1). The
GeneDiseaseAssociation ontology describes the different types of
association between a gene and a disease and was developed to
integrate information from the different databases used in this
study. We inspected the different types of gene-disease associations
included in each of the databases and developed the ontology as a
mean to harmonize them in a common framework. While most of
the databases focus on describing ‘‘true’’ associations between
genes and diseases, some of the databases also contain information
of genes that are known to be not associated to a certain disease
phenotype. Thus, an upper level classification of the associations
based on the level of certainty of the gene-disease association was
used. The ‘‘Association’’ class indicates that there is indeed an
association between a gene and a disease; and the ‘‘NoAssocia-
tion’’ class indicates that there is no association between a gene
and a certain disease state. This can also be expressed as
independence between a certain state of the gene/protein and the
disease state. Two data sources (PharmGKB and LHGDN)
provide associations that were mapped to the class ‘‘NoAssocia-
tion’’, in particular associations labeled ‘‘not related’’ from
PharmGKB and ‘‘negative association’’ from LHGDN.
Consequently, we classified all association types as found in the
original source databases into Association if there is a relationship
between the gene/protein and the disease, and into NoAssociation if
there is no association between a gene/protein and a certain
disease (in other words, if there is evidence for the independence
between a gene/protein and a disease). In this study, we only con-
sidered gene-disease associations of type Association. The ontology is
available at http://ibi.imim.es/DisGeNET/DisGeNETweb.
html#Download.
Mapping of disease vocabularies and disease
classification
We used the Medical Subjects Headings (MeSH) hierarchy for
disease classification (see http://www.nlm.nih.gov/mesh/). The
repositories of gene-disease associations use two different disease
vocabularies, MIM terms (used by OMIM, UniProt, CTD) and
MeSH terms (used by CTD, PharmGKB, LHGDN). We used the
UMLS metathesaurus to map from MIM to MeSH vocabularies.
This step was performed to merge disease terms representing the
same disorder, thus reducing redundancy. We were able to map
497 MIM terms directly to MeSH using UMLS and we
additionally mapped 23 MIM terms by using a string mapping
approach. Briefly, we searched the UMLS metathesaurus for
MeSH terms for which there is at least one synonym exactly
matching one of the synonyms describing the MIM term of
interest. The resulting 63 matched terms were manually checked
and reduced to 23 terms. For disease classification, we considered
all 23 upper level concepts of the MeSH tree branch C (Diseases),
plus two concepts (‘‘Psychological Phenomena and Processes’’ and
‘‘Mental Disorders’’) of the F branch (Psychiatry and Psychology).
Moreover, we added one disease class ‘‘Unclassified’’ for all
disease terms for which a classification was not possible. We
categorized all diseases into one or more of the 26 possible disease
classes. For MeSH disease terms we directly used its position in the
MeSH hierarchy, for MIM disease terms not mapped to MeSH,
we used the disease classification of [22]. Then, we mapped their
disease classification to the MeSH hierarchy and extended the
mapping using a disease classification available at CTD (CTD_di-
sease_hierarchy.tsv downloaded August, 8th 2009). In total, we
were able to classify 3980 (98.39%) diseases. The disease
classification allows filtering and searching of the network
restricted to disease class, all implemented within DisGeNET
[28]. The disease classification is available as text file in the
supplementary material (Text S2). Many diseases are assigned to
more than one disease class as several systems or organs are
affected. Fig. S4 shows the disease color mapping used in
DisGeNET [28]. Disease and gene nodes can be colored
according to their disease class and can have multiple colors if
they are assigned to more than one disease class.
Generation of gene-disease networks
The gene-disease associations can be represented as bipartite
graphs, which have two types of vertices and the edges run only
between vertices of unlike types [67]. Accordingly, we constructed
four different networks, OMIM, CURATED (containing associ-
ations from expert curated databases), LHGDN (text-mining
derived associations) and ALL (containing all associations). In our
networks, multiple edges represent the multiple data sources
reporting the gene-disease association. We generated two
projections, one for the diseases and one for the genes using the
igraph library in R [68]. The projected networks contain only
vertices of the same kind (monopartite) and two nodes are
connected if they share a neighbor in the original bipartite graph.
Before calculating node degree distributions and projecting the
networks, we simplified the graphs by removing multiple edges. In
the simplified graphs the node degree represents the number of
first neighbors.
All gene-disease networks are available as SQLite database and
through DisGeNET, a Cytoscape plugin, both available online at
http://ibi.imim.es/DisGeNET/DisGeNETweb.html#Download.
Graph clustering
To identify clusters in the disease and gene projection networks,
we used the MCL graph cluster algorithm [69], which has
successfully been applied to protein family detection [70]. We




,we(v1,v2)[ 0,1    ð1Þ
where e(v1, v2) is the edge connecting vertices v1 and v2 and av is
the number of annotations to vertex v (genes to disease nodes or
diseases to gene nodes). Edge weights range from zero to one
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annotations of the node with less annotation.
Pathway homogeneity
It has been shown that for OMIM diseases the associated genes
are involved in the same biological and cellular processes
[17,22,71]. In order to test if this concept applies for our integrated
data set, we calculated pathway homogeneity for (i) each disease
separately, (ii) for the disease clusters and (iii) the gene clusters.
Homogeneity is defined as the maximum fraction of genes








where ni is the total number of genes in the disease, disease cluster
or gene cluster (i) with annotations, and n
j
i is the number of genes
sharing the same biological annotation (j). The pathway
annotation was downloaded from KEGG (ftp://ftp.genome.jp/
pub/kegg/genes/organisms/hsa) and Reactome (http://www.
reactome.org/download/index.html) on November, 11
th 2009.
To calculate random controls for pathway homogeneity for
single diseases and disease clusters, we randomly sampled genes
from the set of disease genes of the studied network with
annotation to pathways. We then took the annotation of the
corresponding gene products and calculated pathway homogene-
ity values. Random controls for gene clusters were obtained by
randomly assigning genes to clusters while total number of clusters
and original cluster sizes were maintained. Random sampling was
repeated 10
4 times to reach statistical significance and averages
were compared to real values. We use a significance level of 0.05.
Moreover, binning of cluster sizes was performed to show
dependence of cluster sizes and homogeneity values, for the bin-
wise comparison of mean values, 95% confidence intervals were
calculated. To study the correlation between homogeneity values
and the number of associated gene products we calculated the
Pearson correlation coefficient (r).
HINscore calculation
To evaluate if disease genes products belonging to our clusters
are more likely to interact directly than randomly selected genes
we calculated the HINscore using the recently published human
interaction network (HIN) [36]. HIN is based on protein-protein
interaction data from HPRD and pathway data from Reactome,
NCI/Pathway Interaction database and the MSKCC Cancer Cell






where cc is the number of connected components of subgraph sg
built using all nodes in clusteri connected by edges appearing in the
human interaction network (HIN), and n is the total number of
gene products in clusteri. The HINscore reflects the degree to which
the gene products in a cluster are connected between them in
terms of direct (physical) interactions. The HINscore is 1 if all
nodes in a cluster are directly connected in HIN; it is 0 if they are
not connected in HIN but only in the gene cluster due to shared
disease associations. Therefore, the HINscore represents a means
to measure to what extent the gene clusters represent functional
modules and hence to measure the modularity of human diseases.
We compared the HINscores with random controls for all four
networks. For the random controls, we randomly selected the
same number of genes per cluster from the samples set consisting
of all genes in the network of study being present in HIN. We
repeated the randomization process 10
4 times to achieve statistical
significance. We display mean HINscore for different cluster sizes
and 95% confidence intervals. We use a significance level of 0.05.
Supporting Information
Figure S1 Gene-disease association ontology. Gene-
disease association ontology developed to allow correct integration
of information from diverse repositories.
(TIF)
Figure S2 Number of distinct gene/disease nodes and
edges per data source. The number of diseases refers to the
actual number of disease nodes in the networks after mapping of
disease vocabularies. The number of edges (simplified) refers to the
number of distinct gene-disease associations. The number of edges
(multiple) represents all edges, considering one edge for each
source or evidence reporting the gene-disease association.
(TIF)
Figure S3 Venn diagrams of data overlap among
databases. The upper panel shows the overlaps among the
individual expert curated databases. The lower panel displays the
overlap of CURATED and the text-mining derived network
(LHGDN).
(TIF)
Figure S4 Disease classes visualization in DisGeNET.
Diseases were classified into 26 disease classes according to the
MeSH hierarchy allowing the analysis of groups of related diseases
based on standard disease classification. Using this disease
classification, many diseases are assigned to more than one disease
class as different systems or organs are affected.
(TIF)
Figure S5 Degree distributions of the bipartite net-
works. The node degree distributions of the bipartite networks
are plotted showing (A) the number of associated genes per disease
and (B) the number of associated diseases per gene. Red arrows
highlight the two disease- or gene-nodes with highest degree.
Moreover, average degree values are plotted.
(TIF)
Figure S6 Pathway homogeneity for disease clusters.
Mean pathway homogeneity values for different number of
associated gene products are plotted and compared to random
controls (CI 95%).
(TIF)
Figure S7 Pathway homogeneity for gene clusters. Mean
pathway homogeneity values for different number of associated
gene products are plotted and compared to random controls (CI
95%).
(TIF)
Text S1 Supplementary material describing topological an
functional network analysis and statistics on gene annotations.
(DOC)
Text S2 Disease terms from DisGeNET and their classification
according to MeSH (tab separated file).
(TXT)
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